Auxiliary liver transplantation (ALT) for hepatitis B virus (HBV)-related liver cirrhosis previously showed poor results, because the native liver was a significant source of HBV recurrence and the graft could be rapidly destroyed by HBV infection in an immunosuppressive condition. Four patients with HBV-related liver cirrhosis were unable to undergo orthotopic liver transplantation because the only available grafts of left lobe were too small. Under entecavir-based anti-HBV treatment, they underwent ALT in which the recipient left liver was removed and the small left lobe graft was implanted in the corresponding space. The mean graft weight/recipient weight was 0.49% (range, 0.38%-0.55%). One year after transplantation, the graft sizes were increased to 273% and the remnant livers were decreased to 44%. Serum HBV DNA was persistently undetectable. Periodic graft biopsy showed no signs of tissue injury and negative immunostaining for hepatitis B surface antigen and hepatitis B core antigen. After a mean follow-up period of 21 months, all patients live well with normal graft function. Our study suggests that ALT for HBVrelated liver cirrhosis is feasible under entecavirbased anti-HBV treatment. Successful application of small left livers in end-stage liver cirrhosis may significantly increase the pool of left liver grafts for adult patients.
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Introduction
Orthotopic liver transplantation is often the definitive therapy for patients with end-stage liver disease of various etiologies. One limitation, however, is that orthotopic liver transplantation precludes the chance for recovery of the host liver in acute liver failure. A second limitation is the paramount limitation of organ shortage or graft size, resulting in high mortality rates while patients are on the waiting list. Auxiliary liver transplantation (ALT), which is implanting a healthy liver while leaving the native liver in situ, is an attractive alternative because the two livers will co-function and support each other. In acute liver failure, a liver graft is implanted to temporarily correct liver function while waiting for complete native liver regeneration, after which immunosuppression can be withdrawn (1) (2) (3) . In noncirrhotic metabolic liver disease, a very small graft, which can compensate for the only defect of a liver enzyme, and the noncirrhotic native liver can work together permanently to sustain normal liver function (4) (5) (6) . In chronic cirrhotic liver disease, the native liver and the implanted small-for-size graft can function together to save the life of a recipient during the immediate postoperative period, and then the small graft will regenerate rapidly to be large enough even when the native liver is removed (7). However, ALT for hepatitis B virus (HBV)-related liver cirrhosis, a major indication for transplantation, had shown poor results and was suggested as a contraindication because the native liver was a significant source of HBV and the graft was destroyed rapidly by HBV in the immunosuppressive condition (7) (8) (9) .
In this report, we describe favorable outcomes in the first four patients with end-stage HBV liver cirrhosis who underwent ALT along with an anti-HBV therapy after they were excluded from consideration for living donor liver transplantation or split left lobe liver transplantation in common practice, because of concerns regarding living donor safety or inadequate left lobe volume.
Patients and Methods
In the evaluation of living donor liver transplantation, if left lobe graft weight/recipient weight (GW/RW) is <0.8% or graft volume/recipient standard liver volume (GV/SLV) is <40%, the left lobe is not large enough to meet the hepatic function demand of the recipient. If the remnant left lobe volume/standard liver volume in the donor is <35%, the right lobe cannot be donated to secure donor safety (10) . In this situation, we have to consider left lobe ALT (LL-ALT) in which we preserve a portion of the recipient liver and implant a left lobe from the donor to allow them function together. Another situation is that when we perform split liver transplantation during the times of rare availability of deceased donors, sometimes the left lobe also is not large enough, and we need to reconsider LL-ALT to use the precious left lobe in adult recipients. With approval from the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, LL-ALT was performed in four patients with HBV-related liver diseases between November 2013 and November 2014. Informed consent was obtained from the recipient and the living donor, both of whom accepted the risks and benefits of LL-ALT. A potential organ donor orally expressed a will to donate before brain death due to primary brain tumor and his organ was donated after cardiac arrest (Maastricht category IV donor) with written consent from his closest relative. This precious liver was decided to be split because the assigned sickest recipient had a slim physique and could accommodate only the right liver. The split left liver was then considered for a candidate (patient A) with a relatively low Model for End-stage Liver Disease (MELD) score of 25 for the sake of safety who had been on the waiting list for more than 8 months. All the four ALT recipients were not willing to wait for the next opportunity of a whole liver due to the serious lack of deceased donors in 2014 in our country (11) . The data were collected prospectively.
Three left lobe liver grafts were procured from living donors, and the fourth was procured from the donor after cardiac death. There was preoperative assessment of live donor liver volume and no feasibility of conventional living donor liver transplantation ( Table 1) . The etiology of all recipients' chronic liver disease was HBV, except one patient who was coinfected with Schistosoma japonicum. The indication for liver transplantation was decompensated liver cirrhosis, including concurrent hepatocellular carcinoma in the left liver of one patient. Severity of liver disease was expressed by native MELD score on liver transplantation ( Table 2 ). The preoperative liver volumes of recipients was also measured, by using clinical computed tomography (Table 3 ). All patients received an entecavir-based anti-HBV regimen for a period of 2-49 months, and HBV was not detectable before liver transplantation. One of the patients was given a combined treatment of entecavir and adefovir dipivoxil because she was resistant to lamivudine treatment of 18 months at the L180 and M204 sites. Clinical characteristics of the donors and recipients are summarized in Table 2 .
Living donors underwent left lobe procurement without middle hepatic vein according to the generally described method (14) . The ex vivo procedure of harvesting a split left lobe was similar to that in a living donor operation. All recipients underwent LL-ALT, in which the recipient left liver is resected and the left lobe graft is implanted in the corresponding space. The left hepatic vein, left portal branch, and left hepatic artery of the graft liver were anastomosed to the same respective vessels in the recipient. Except in the patient with portal vein cavernous transformation (patient C), a cryopreserved iliac vein conduit was interposed between the donor portal vein and the recipient superior mesenteric vein. The bile duct of the grafted liver was anastomosed to the left hepatic duct or Roux-en-Y limb, and a small external drainage tube was placed at the anastomotic site. Hepatic arteries were always reconstructed under microscopic guidance. We also performed simultaneous splenectomy in one patient (patient A) because of insufficient abdominal space.
After transplantation, in addition to maintaining the anti-HBV drug, we adopted a composite strategy consisting of volume-electrolyte balance, infection prevention, immunosuppression, gastric secretion inhibition, liver function protection, nutritional support, and anticoagulation therapy. The immunosuppressive regimen with simulect and steroid induction consisted mainly of tacrolimus at a dosage to maintain a plasma concentration between 6 and 10 ng/mL. As postoperative anticoagulation therapy, sulodexide and prostaglandin E1 (for 1 week) were administered intravenously on the second or third day after surgery, provided no frank bleeding was observed in abdominal drains, and then oral sulodexide continued for 3 months. Regular examination was made, including blood routine tests, liver and kidney function tests, electrolyte tests, coagulation, liver ultrasound, FK506 concentration, and serum HBV DNA. Doppler ultrasound was done to confirm the patency of liver vessels and to measure blood flow velocities daily during the first posttransplantation week and twice a week thereafter until discharge. Postoperatively and then at 1, 3, and 12 months, computed tomography scanning or magnetic resonance imaging was performed to measure the volume of the graft and the native liver. The conversion factor between liver volume and liver weight is 1.0 g/ mL. Liver biopsy specimens from grafts were taken at 1, 6, and 12 months after transplantation for routine pathological examination and immunostaining of hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg). Any other examination was suitable when indicated. We evaluated postoperative complications, such as bleeding, thrombosis, acute rejection, infection, and biliary leakage and stricture, as well as others. The GW (graft weight) equals to estimated graft volume because the density of liver tissue is 1.0 g/mL. This was the reason for rejecting conventional living donor liver transplantation. If GW/RW is <0.8%, the estimated graft cannot be donated to ensure recipient result. If RLV/WLV is <35%, the estimated graft cannot be donated to secure donor safety.
Results

Effective control of HBV replication
With use of preoperative anti-HBV treatment regimen after liver transplantation, although all recipients were positive for serum HBsAg, the replication of HBV DNA was persistently undetectable. There also were no histological changes suggesting tissue injury or recurrent hepatitis from periodic liver biopsy specimens of the liver graft at 1, 6, and 12 months after transplantation. Moreover, immunostaining for HBsAg and HBcAg was negative in all specimens.
Interactive volume change between the graft and the native liver The mean estimated volume of the resected native left liver was 338 mL (range, 301-392) and that of the remnant right liver was 532 mL (range, 346-687). The actual volume of the implanted left lobe graft varied from 242 to 307 mL (mean, 284).
The volume growth of the liver graft from the operation to 1, 3, and 12 months after the transplantation is shown in Figures 1 and 2 . While the graft size grew over time, the native right liver atrophied (Figures 1 and 2 ). One year after transplantation, the graft size was increased to 273% (range, 231%-318%) and the remnant right liver was decreased to 44% (range, 17%-82%). In the patient D, hepatic vein occlusion was detected on postoperative Esophageal varice is categorized according to Italian Liver Cirrhosis Project (13) . Small: small straight varices; medium: enlarged tortuous varices occupying less than one-third of the lumen; large: large coil-shaped varices occupying more than one-third of the lumen. day 75, resulting in shrinkage of the graft and growth of the native liver from postoperative month 1 to month 3. When the hepatic vein occlusion was corrected via balloon dilation, the normal tendency of volume change was restored.
Recovery of the recipients
The measured graft weight varied between 242 and 307 g (mean, 284). The mean GW/RW and GV/SLV values were 0.49% (range, 0.38%-0.55%) and 24% (range, 19%-27%), respectively. The total cold ischemia time was 9.4 h for the split graft and 2.9 h (range, 2.3-3.5) for the three living grafts.
The mean transplantation time and intraoperative blood loss were 10.3 h (range, 8.5-13.2) and 2550 mL (range, 800-5200) respectively. All grafts produced bile immediately after transplantation. Portal vein peak velocity measured in the native and grafted livers ( Figure 3) by Doppler ultrasound to some extent reflected the distribution of portal vein flow into the two livers. The postoperative values for serum alanine aminotransferase, bilirubin level, and international normalized ratio (INR) intermittently fluctuated but gradually decreased to normal levels at 1 month. Although patient C underwent ultrasoundguided drainage for a bile leak from the cut surface and cefoperazone sodium/sulbactam sodium treatment for a pulmonary infection with Acinetobacter baumannii, all recipients recovered uneventfully and were discharged after surgery.
During regular follow-up, in patient D, hepatofugal flow in the portal vein of the liver graft at postoperative day 75 was detected on Doppler ultrasound, and it was found that it was due to occlusion of the graft's hepatic vein. The patient underwent a balloon dilation of the occlusive hepatic vein, and portal vein flow to the graft was restored. At 13 months after transplantation, the patient's liver function maintains normal. In patient B, who was transplanted due to HBV liver cirrhosis and hepatocellular carcinoma, we finally resected the retained native liver when two recurrent lesions were found in the native liver 10 months after liver transplantation. This patient had been re-followed for 16 months after the resection. The hepatic function provided by the liver graft alone satisfactorily meets all demands of the recipient, and no lesion was found in the graft.
After a mean follow-up period of 21 months (range, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , all recipients are alive and well with normal graft function as demonstrated by liver function test, synthesis of clotting factors, and Image examination.
Recovery of living donors
The mean age of all donors was 48 years (range, 40-59). One living donor developed a minor bile leak from the cut surface, which was healed with percutaneous drainage. All living donors were able to resume their normal lives after discharge from the hospital.
Discussion
The use of ALT for patients with chronic HBV liver disease is currently precluded because the inevitable recurrence of HBV infection in the graft resulted in a high rate of graft loss (7) (8) (9) . A pathological study clearly showed that recurrence of HBV infection in ALT is demonstrable within 1-3 weeks and aggressively resulted in cirrhotic transformation of the graft within 1 year (8) . Passive immunoprophylaxis with hepatitis B immunoglobulin does not protect recipients whose livers with HBV are wholly or partially preserved and may lead to an immune complex disease. Efficacy of antiviral drugs (such as entecavir and tenofovir) has been proved in patients with HBV infection (15, 16) or even in patients with HBV recurrence in liver graft (17) ; however, many doubts remain with regard to ALT for HBV-related liver cirrhosis, because the severity of the graft infection can be greater if the host liver, an HBV pool, is left in situ.
In the present series, no recipients showed HBV recurrence in the auxiliary liver graft, as suggested by the persistently undetectable viral load, normal liver histology, and negative immunochemical staining of HBV antigens. The results are somewhat surprising because the noninfected liver graft and the previously infected native liver can coexist safely under the circumstance of appropriate antiviral therapy. On the basis of this series, we believed that chronic HBV infection should not be considered as a contraindication for ALT in patients with end-stage liver cirrhosis.
ALT can lower the volume requirement for the graft, because the preserved native liver can function to some extent and support the partial liver graft to quickly regenerate to be large enough. A requirement in partial liver transplantation is that graft volume should be larger than 40% to 50% of the recipient standard liver volume to satisfy the metabolic function in the recipients (10) . The left liver constitutes about one-third (33%) of a whole liver in human, so it generally cannot be donated to an adult patient. The three cases in this report were previously excluded for living donor liver transplantation and subsequently underwent LL-ALT with living donors. The remaining case received a cadaveric left lobe graft in a similar situation. The GV/SLV in our series was all <30%, even with a 24% and another 19%. To our knowledge, it is the first time that LL-ALTs were successfully performed in patients with HBV-related liver cirrhosis. A report published in 1999 (7) indicated that two cases underwent a similar ALT procedure for HBV liver cirrhosis and died within 35 postoperative days. Based on this series, we believe that LL-ALT is feasible and may significantly increase the number of liver grafts for adult patients, for those with uncommon liver diseases stated in several reports (7, 18, 19) or those with common HBV disease as described by us. In the past, left lobe liver transplantation with cadaveric split or living donor graft nearly solved the problem of liver donor scarcity in the treatment of pediatric patients. Moreover, left lobe donation will substantially decrease the surgical risk of a living donor in comparison with right lobe donation from the same donor (20) .
During these times of a serious lack of deceased donors and evaluation of an available living donor, we consider LL-ALT when the ratio of left liver to right liver is too small to donate either of the two hemi-livers. Another rare circumstance is that a precious small-forsize left lobe from a split deceased liver was used for an adult patient. The mechanism of small liver graft dysfunction is mainly involved with portal vein hyperperfusion exaggerated by portal hypertension. The successful application of auxiliary small liver grafts in the treatment of end-stage liver cirrhosis highly depends on the redistribution of portal venous blood and metabolic burden between the preserved native liver and the small graft. How does one choose an appropriate recipient with certain residual liver function to support auxiliary small liver grafts, and with relatively low portal hypertension to avoid liver graft damage by portal vein hyperperfusion? There are multiple considerations similar to those in general partial liver transplantation, such as recipient liver function, degree of portal hypertension, graft size and quality, surgical issues, and others. In ALT, remnant liver volume and function are also important factors. However, there is no accurate and reliable method to measure liver function reserve and degree of portal hypertension. Preoperative Child and MELD scores are recognized to be closely correlated to liver function reserve, the degree of portal hypertension, and patient prognosis (21) . The performance status according to the Eastern Cooperative Oncology Group would also be helpful in evaluation of the severity of liver disease (22) . We believe that if a patient is categorized into grade 1-3 and is not bedbound and is capable of all or limited self-care, then his or her diseased liver should have certain stable liver function to maintain his or her life and activity and can support the small liver graft through the early postoperative period to regenerate. We suggest that a patient with a MELD score of 25 or less and performance status not higher than grade 3 can have a choice of ALT.
Tremendous efforts had been made to increase the pool of liver grafts by establishing reduced-size (23), split deceased (24) , living donors (25) , cardiac death (26) , and even xenogenic liver grafts (27) and to decrease the risk of living right hemi-liver donors by designing complex types of liver graft such as the left liver with the left-side caudate lobe (28) , the right lateral sector graft (segments VI and VII) (29) , and even the dual living donor liver grafts (30) . LL-ALT can expand the donor pool and significantly decrease living donor risk, although it is associated with some technical difficulty in recipients. Improvement in outcomes has been clearly illustrated by our results as well as those of recent series (19, 31) .
The number of patients in this study was small, yet our data suggest an important role of ALT in treating HBV-related end-stage liver cirrhosis, even with very small grafts, in the modern era with highly efficient anti-HBV drugs. ALT can make those left liver grafts from a living donor and a split source more widely applicable and contribute to increasing the pool of liver grafts for adult patients.
